EUCTR2015-000799-92-FR进行中（未招募）1 期
A randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of Alirocumab in insulin treated patients with type 1 or type 2 diabetes and with hypercholesterolemia at high cardiovascular risk not adequately controlled on maximally tolerated LDL-C lowering therapy. - ODYSSEY DM-Insulin
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 500
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Patients with type 1 or type 2 diabetes treated with insulin whose LDL-C levels are not adequately controlled with maximally tolerated lipid-modifying therapy.
- •LDL-C of 70 mg/dL or greater.
- •18 years of age or more.
- •Glycosylated hemoglobin (HbA1c) less than 10%.
- •History of cardiovascular disease (including CHD and/or CHD risk equivalents) and/or at least one additional cardiovascular risk factor.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 300
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 200
排除标准
- •Not on a stable dose of statin or other lipid modifying therapy for at least 4 weeks prior to screening.
- •Triglycerides >400 mg/dL.
- •Estimated glomerular filtration rate (eGFR) <15 mL/min/1.73 m^2 according to modification in diet of renal disease (MDRD) equation.
- •Currently receiving or plans to receive renal replacement therapy (for example, hemodialysis).
- •Change in weight of more than 5 kilograms within the prior 2 months.
- •Not on a stable dose/regimen of insulin or other antidiabetic drugs for the past 3 months or plans to intensify insulin regimen during the study.
- •Not treated with insulin for at least 6 months.
- •Plans to start new lipid modifying therapy or change dose of current lipid modifying therapy during the study.
- •Body mass index (BMI) >45 kg/m^2 or plans to undergo bariatric surgery, weight loss program, or initiate weight loss drugs during the study.
- •History of recent decompensation of diabetes within the prior 2 months (for example, diabetic ketoacidosis).
研究者
相似试验
进行中（未招募）
1 期
Efficacy and safety of finerenone in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic kidney diseaseType II Diabetes Mellitus and Diabetic Kidney DiseaseMedDRA version: 21.1Level: PTClassification code 10061835Term: Diabetic nephropathySystem Organ Class: 10038359 - Renal and urinary disordersEUCTR2015-000990-11-DEBayer AG9,600
进行中（未招募）
1 期
A study to investigate if inhaled Interferon beta-1a is safe, and could prevent or reduce the severity of asthma attacks when administered to asthma patients at the onset of a virus affecting their airways (e.g. common cold or influenza)AsthmaEUCTR2014-005084-32-GBAstraZeneca AB121
进行中（未招募）
1 期
A randomized, double-blind, placebo-controlled, parallel-group, fixed-dose (rimonabant 20mg) multicenter study of long-term glycemic control with rimonabantin treatment-naïve patients with type 2 diabetes - SERENADEPatients with Type 2 diabetes not treated by a pharmacological agent.MedDRA version: 7.0Level: LLTClassification code 10045242EUCTR2004-004881-34-GBSanofi-Synthelabo Recherche264
进行中（未招募）
不适用
Efficacy and safety study of QAW039 in the treatment of patients with moderate to severe atopic dermatitisAtopic dermatitisEUCTR2012-005321-78-DEovartis Pharma Services AG92
进行中（未招募）
不适用
A randomized, double-blind, placebo-controlled, parallel-group design study to evaluate the efficacy and safety of teriflunomide (HMR1726D) in reducing the frequency of relapses and delaying the accumulation of physical disability in subjects with multiple sclerosis with relapses - TEMSOEUCTR2004-000555-42-ITsanofi-aventis Recherche & De`veloppement870